We are happy and proud that our NIF mouse is the model used in the preclinical poster presented by Cymabay Therapeutics at the upcoming AASLD meeting, with the title “Seladelpar reduces established liver and renal fibrosis in the non-obese diabetic inflammation and fibrosis (NIF) mouse model”Take a look at the press release here!